Hansoh Pharmaceutical Group Company Limited (HNSPF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
As of 03:54PM EDT. Market open.
| Previous close | 1.8800 |
| Open | 1.8800 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 1.8800 - 1.8800 |
| 52-week range | 1.5000 - 1.8800 |
| Volume | |
| Avg. volume | 3 |
| Market cap | 13.648B |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | 26.86 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.03 (1.45%) |
| Ex-dividend date | 20 June 2024 |
| 1y target est | N/A |
- GlobeNewswire
SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
JERSEY CITY, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that China’s National Medical Products Administration (NMPA) has accepted for review a New Drug Application (NDA) for oral ibrexafungerp tablets for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC) in the Chinese mainland.
© 2024 Yahoo. All rights reserved.